Anti-CD79B (Polatuzumab Vedotin), Humanized Antibody

Anti-CD79B (Polatuzumab Vedotin), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is an antibody-drug conjugate that targets CD79B. CD79B is a transmembrane protein that plays an essential role in B-cell receptor signaling and is highly expressed on the surface of tumorigenic cells. The conjugate consists of Anti-CD79B humanized monoclonal antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and apoptosis of tumorigenic cells. The original antibody-drug conjugate has been approved by the FDA to treat patients with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab.

Immunogen Sequence:Human CD79B

Target Alternative Name:B29, IGB, AGM6, fcu 2711, Ro 5541077-000, DCDS4501A, RG7596

Species Reactivities:Human

Tag Line:The biosimilar is an antibody-drug conjugate that targets CD79B. Upon detachment from the antibody inside the cell, the drug disrupts microtubule network, which leads to cell cycle arrest, and apoptosis of malignant cells

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.